Scope of the Study
Hyperhidrosis is a condition characterized by excessive sweating that is not necessarily related to heat or exercise. It is estimated that roughly 3% of the world’s population i.e. around 200 million people have this medical condition. It can affect just one specific area or the whole body. It is normally most active in the hands, feet, armpits, and the groin because of their relatively high concentration of sweat glands. It may be present from birth or might develop later in life. Hyperhidrosis treatment depends on the type of hyperhidrosis and where the excessive sweating occurs on the body.
The market study is being classified by Type (Antiperspirants, Iontophoresis, Botulinum toxin injections, Prescription cloth wipes, Prescription medicine and Surgery), by Application (Hospitals, Dermatology Clinics and Other) and major geographies with country level break-up.
Allergan, Inc. (United States), GlaxoSmithKline Plc (United Kingdom), Revance Therapeutics Inc. (United States), Ulthera, Inc. (United States), TheraVida, Inc. (United States), Dermira, Inc. (United States) and Sientra Inc. (United States) are some of the key players profiled in the study.
Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Hyperhidrosis Treatment market throughout the predicted period.
AdvanceMarketAnalytics has segmented the market of Global Hyperhidrosis Treatment market by Type, Application and Region.
On the basis of geography, the market of Hyperhidrosis Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increase in the Prevalence of Hyperhidrosis
- Development of New Diagnostic Centres and Hospitals
- Increase in the Research Activities
- Growing Focus on Preventive Healthcare
- Less Awareness among People
- Rising Regulatory Approval for Hyperhidrosis Medicines
- Growing Healthcare Industry Worldwide
- Stringent Government Rules and Regulations
Market Leaders and their expansionary development strategies
In January 2019, GlaxoSmithKline plc has announced that it has successfully completed the acquisition of TESARO, Inc. an oncology-focused company based in Waltham, Massachusetts.
Key Target AudienceHyperhidrosis Treatment Providers, Research Professionals, Emerging Companies, Distributors, Government Body and Associations and End-users
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase